BofA upgrades Pharvaris stock rating on oral HAE treatment potential

BofA upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing potential in its oral HAE treatment. The stock trades at $30.68, up 10.6% in a week. Positive phase 3 data and strong analyst ratings highlight its prospects, despite risks like market adoption and competition.

Original reporting
Published Oct 23, 2026, 11:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 11:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$PHVS
Bullish
high confidence
Mentioned
$PHVS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PHVSBullishHigh
01

Why it matters

The Buy rating and $44 target provide a clear catalyst for short‑term buying pressure.

02

Market read

Analyst upgrade on a micro‑cap biotech with recent positive trial data, offering a near‑term trade idea.

03

What to watch

Potential competition from injectable therapies and regulatory timelines beyond 2027.

Relevance 7/10Novelty 6/10Timing: today

Background

Pharvaris reported positive Phase 3 oral HAE data in September 2024; the upgrade reflects fresh analyst confidence.

Company-level read

Ticker impact

$PHVSBullishHigh confidence
Context

BofA upgraded Pharvaris to Buy with a $44 target, citing strong Phase 3 data and a 10.6% recent price gain.

Expected impact

likely upward pressure as traders price in the new Buy rating and target.

Evidence & confidence

Upgrade is a fresh, actionable recommendation with a concrete price target, providing a clear catalyst for buying.

Market effects

Positive for the rare‑disease biotech sector as the upgrade highlights clinical progress.

US biotech market may see modest buying interest.

Limited to investors tracking rare‑disease therapeutics.

Counterpoint

The upgrade may be premature if long‑term safety or market adoption issues emerge.

Key entities

  • BofA Securities

    Upgraded Pharvaris to Buy and set a $44 price target.

  • Pharvaris B.V.

    Biotech developing oral HAE treatment deucrictibant.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.